skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Procalcitonin NH2-terminal cleavage peptide has no mitogenic effect on normal human osteoblast-like cells

Journal Article · · Journal of Bone and Mineral Research; (United States)
; ; ; ; ;  [1]
  1. Endocrine Research Unit, Mayo Clinic, Rochester, MN (USA)

The NH2-terminal cleavage peptide of procalcitonin (N-proCT) recently was reported to be a bone cell mitogen. The authors have investigated the effect of N-proCT on the proliferation of normal human cells that have the phenotype of mature osteoblasts (hOB cells). N-proCT treatment for 24, 48, or 96 h in concentrations from 1 nM to 1 microM did not significantly increase (3H)thymidine uptake (means ranged from -19% to 38% of control, no significant differences) in hOB cells (6-10 cell strains per experiment) plated at four different densities. However, the hOB cells responded significantly to treatment with transforming growth factor {beta} (3 ng/ml), bovine insulin (300 micrograms/ml), or 30% fetal calf serum, which were included in all experiments as positive controls. The (3H)thymidine uptake data were confirmed in a direct cell count experiment tested at 96 h. Thus they data do not support the hypothesis that N-proCT is a potent mitogen for normal human osteoblasts.

OSTI ID:
5464031
Journal Information:
Journal of Bone and Mineral Research; (United States), Vol. 6:5; ISSN 0884-0431
Country of Publication:
United States
Language:
English